SIGLEC Phase 2b data support AVD-104 as a potential therapy to reduce GA lesion growth, preserve and improve visual acuity, and reduce conversion to neovascular AMD across all GA lesion types at 1 ...

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...

Background There are limited treatment options to improve vision in patients with infantile nystagmus. We aimed to examine ...

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injectionTH103 was ...

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

Spot the difference puzzles test your observation skills and focus. Think you have exceptional visual acuity? Go ahead and ...

Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective ...

Optical illusions with hidden images are real-time tests of your observation power. Test your visual processing skills with ...

Aviceda said that imbalances in key baseline lesion characteristics across treatment arms contributed to the lesion-growth ...

The association between falls and visual function is shaped by living in homes with environmental hazards, according to a ...

The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...